In 2014, BELLUS Health entered into a development and license agreement with AMO Pharma Limited (AMO Pharma) for the worldwide rights to AMO-01 (formerly TLN-4601) for the treatment of neurologic and psychiatric disorders in return for royalties on sales and revenue sharing. TLN-4601 was acquired by BELLUS Health as part of the Thallion acquisition in 2013.

AMO Pharma is a private company focused on the treatment of central nervous system and neuromuscular diseases. AMO Pharma is preparing for a Phase 2 study to evaluate the efficacy of AMO-01 in patients suffering from intellectual disabilities in 2018.

Intellectual disabilities are characterized by significant limitations both in intellectual functioning (reasoning, learning, problem solving) and in adaptive behavior, which covers a range of everyday social and practical skills. This disability has a typical onset before the age of 18 and affects 6.5 million people in the U.S. and 1.5 million people in the U.K. There are currently no approved drugs indicated for the treatment of intellectual disabilities.

Share this

Sign up for email alerts

Email Address *
 
Enter the code shown above.